Business Wire

Cabot Properties Expands European Leadership Team to Capitalize on Increasingly Attractive Logistics Property Market

14.1.2025 18:07:00 CET | Business Wire | Press release

Share

Thomas Schellhorn joins firm as Vice President, Asset Management in Germany; Justin Harvey, Managing Director, Head of UK and Europe, to relocate to London

Cabot Properties, a leading investor, developer and operator of logistics properties throughout the United States, Europe and Asia Pacific, today announced that it has expanded its European leadership team as it continues to grow its presence across the region. The firm has hired Thomas Schellhorn as Vice President to oversee asset management for Cabot’s operations in Germany and the Netherlands. In this role, he will be responsible for leasing and capital improvement programs and will report to Jed Raymond, Senior Director and Head of Asset Management for UK and Europe. Justin Harvey, Managing Director and Head of UK and Europe, will relocate to Cabot’s London office to continue leading the firm’s overall strategy and operations across Europe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114998320/en/

null

Thomas Schellhorn, Vice President, Asset Management, Germany and The Netherlands (Photo: Business Wire)

“Justin has been an integral member of our team over the last 17 years, contributing to significant growth at Cabot at a key societal inflection point – the growth of the ecommerce sector – which spurred robust demand for high-quality, well-located industrial assets on a global basis,” said Franz Colloredo-Mansfeld, Chairman and CEO of Cabot Properties. “As we recognized the opportunity to expand our investment activity outside the U.S. over a decade ago, he took on the challenging mandate to lead our investment activity and has generated impressive results to date. We’ve since grown our presence in Europe with teams located in the U.K., the Netherlands, and Germany. With Justin in London, the team in Europe is even better positioned to expand our investment activity.”

Cabot has acquired more than 970,000 square meters of logistics properties in Europe and the U.K. since 2011, adding nearly 300,000 square meters to its portfolio in the last two years alone. The company has been active in the German market since 2019 and opened a Munich office in 2024 to support its continued local portfolio growth.

“We see strong opportunity and positive demand tailwinds in the European logistics market, making this a critical moment to expand our team and focus across the region,” said Harvey. “Germany has one of the largest and most important logistics markets in Europe, and Thomas’ depth of knowledge, experience and relationships will give us an excellent advantage for growth in that market. This will help enable our European team to effectively execute a targeted management strategy that we believe will provide long-term value for our investors.”

Schellhorn joins Cabot following four years at Catella Real Estate AG, where he served as a Senior Asset Manager overseeing logistics properties and advising on acquisition and sustainability assessments. His experience in the German logistics real estate space has also spanned several leadership roles at reputable logistics and facility management firms including RLI Investors GmbH, Prologis Germany, DIW Instandhaltung Ltd., and the HOCHTIEF Group. Schellhorn studied facility management at the University of Applied Sciences Kufstein in Austria, graduating as a Qualified Engineer. He is also a Chartered Facility Management Surveyor with the Royal Institution of Chartered Surveyors (RICS).

Harvey has been with Cabot since 2008, having served in various leadership positions throughout the firm’s investment and finance teams prior to taking on his current role in overseeing the firm’s investment activity in Europe. Prior to joining Cabot, Harvey worked at FLAG Capital Management. He holds a Bachelor of Arts from Colby College and a Master of Business Administration from Dartmouth’s Tuck School of Business.

About Cabot Properties

Cabot Properties is an international private equity real estate firm focused on the logistics sector. Founded in 1986, Cabot was one of the first real estate firms to provide institutional investors with access to the industrial property sector and has invested over $15 billion in logistics real estate, served over 4,200 tenants, and operated over 1,600 buildings totaling more than 230 million square feet. Cabot is headquartered in Boston with offices in Atlanta, Chicago, Dallas, Los Angeles, London, Amsterdam, Sydney, Tokyo, and Munich. For more information, visit www.cabotprop.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250114998320/en/

null

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye